Clinical trial
A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome
NCT00282399 · Eisai Inc., Industry · Terminated
Key facts
| NCT number | NCT00282399 |
|---|---|
| Title | A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome |
| Official title | Phase I/II Trial of Subcutaneous Decitabine Maximizing Genomic Demethylation in Patients With Myelodysplastic Syndrome. |
| Lead sponsor | Eisai Inc., Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndrome |
| Intervention type | Drug |
| Interventions | Subcutaneous Decitabine |
| Enrollment | 41 |
| Start date | Oct 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Feb 1, 2009 |
| First posted | Jan 26, 2006 |
| Last update posted | Oct 28, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: